FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Autoimmune Disease topics
Autoimmune Disease
Immune Disease
Autoimmune
Autoimmune Diseases
Immune Diseases
Transplant
Infectious Disease
Infectious
Inflammatory Disease
Antagonist
Rheumatoid Arthritis
Proliferative
Nucleotide
Antibodies
Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Disease patents



      
           
This page is updated frequently with new Autoimmune Disease-related patent applications. Subscribe to the Autoimmune Disease RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune Disease RSS RSS


Date/App# patent app List of recent Autoimmune Disease-related patents
04/23/15
20150111873
 Pharmaceutically active pyrazolo-triazine derivatives patent thumbnailnew patent Pharmaceutically active pyrazolo-triazine derivatives
Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh
04/23/15
20150111872
 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders patent thumbnailnew patent Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .
04/23/15
20150111835
 Modified peptides and their use for treating autoimmune diseases patent thumbnailnew patent Modified peptides and their use for treating autoimmune diseases
The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications.. .
Centre National De La Rechereche Scientifique
04/23/15
20150110805
 Therapeutic strategy for treating autoimmune and degenerative diseases patent thumbnailnew patent Therapeutic strategy for treating autoimmune and degenerative diseases
Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases.
Immunaid Pty Ltd.
04/16/15
20150104866
 Ip-10 antibodies and their uses patent thumbnailIp-10 antibodies and their uses
The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Medarex, L.l.c.
04/16/15
20150104388
 Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use patent thumbnailAnalogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (pacap), which are agonists for the pacap/vasoactive intestinal peptide (vip) receptors: pac1, vpac1 and vpac2 receptors. These pacap analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease.
The Administrators Of The Tulane Educational Fund
04/09/15
20150099770
 Carboxylic acid compounds patent thumbnailCarboxylic acid compounds
The present disclosure concerns at least one entity chosen from compounds of formula (i) and pharmaceutically acceptable salts thereof: (i) wherein the variable groups x, r1, r2, r3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer..
Astrazeneca Aktiebolag
04/09/15
20150099664
 Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases patent thumbnailProtein biomarkers and therapeutic targets for autoimmune and alloimmune diseases
A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.. .
Case Western Reserve University
04/09/15
20150099001
 Nanocell drug delivery system patent thumbnailNanocell drug delivery system
Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
Massachusetts Institute Of Technology
04/09/15
20150098955
 Cd40l-specific tn3-derived scaffolds and methods of use thereof patent thumbnailCd40l-specific tn3-derived scaffolds and methods of use thereof
The present invention provides tenascin-3 fniii domain-based scaffolds that specifically bind to cd40l. The invention further provides engineered variants with increased affinity for the target.
Medlmmune, Llc
04/02/15
20150094319

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
04/02/15
20150093799

Histidyl-trna synthetases for treating autoimmune and inflammatory diseases


The present invention relates generally to compositions and methods comprising histidyl-trna synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to jo-1 antibodies.. .
Atyr Pharma, Inc.
03/26/15
20150087643

Substituted fused pyrimidine compounds


The present invention discloses substituted fused pyrimidine compounds of formula (i), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (ar) activity; the compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.. .
Advinus Therapeutics Private Limited
03/26/15
20150087620

Amine compound and use thereof for medical purposes


Wherein each symbol is as described in the description, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (gvh) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.. .
03/26/15
20150087529

Sequencing analysis of circulating dna to detect and monitor autoimmune diseases


Systems, methods, and apparatuses are provided for diagnosing auto-immune diseases such as systemic lupus erythematosus (sle) based on the sizes, methylation levels, and/or genomic characteristics of circulating dna molecules. Patients provide blood or other tissue samples containing cell-free nucleic molecules for analysis.
The Chinese University Of Hong Kong
03/19/15
20150080391

Novel compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders


The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and their use in the prophylaxis and/or treatment of inflammatory conditions, type 2 diabetes, neurological and/or neurodegenerative diseases, autoimmune diseases, proliferative diseases (in particular metastatic diseases, and/or cancer), abnormal angiogenesis associated diseases, degradation of cartilage, and/or disruption of cartilage homeostasis, in particular in the prophylaxis and/or treatment of cancer. The present invention also discloses methods of treatment using the same compounds, for the prophylaxis and/or treatment of said diseases by administering the compound of the invention..
03/19/15
20150080369

Novel compounds


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited
03/19/15
20150080356

Method for improving therapy for autoimmune diseases such as rheumatoid arthritis


In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases.
Toyama Chemical Co., Ltd.
03/19/15
20150079155

Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood


This invention concerns a liposome comprising lipids and at least one active ingredient, wherein at least one of the lipids is a cationic lipid; said liposome exhibiting a net positive charge at physiological conditions at which said liposome preferentially adheres to monocytes in freshly drawn blood when compared to adherence to granulocytes, t-lymphocytes, b-lymphocytes and/or nk cells in freshly drawn blood, to a lipid-based pharmaceutical composition comprising said liposomes and their use in monocytic associated prophylaxis, treatment or amelioration of a condition such as cancer, an infectious disease, an inflammatory disease, an autoimmune disease or allergy.. .
Danmarks Tekniske Universitet
03/19/15
20150079052

Methods for amelioration of autoimmune disease using stem cells transduced with t cell receptors from il-10 secreting t cells


Methods, cells and vectors are provided for treating a subject for an autoimmune disease using stem cells transduced with genes encoding t cell receptors from il-10 secreting regulatory t cells. The il-10 secreting regulatory t cells are obtained from a donor of stem cells, the donor having been immunized with peptidic compositions used in the treatment of the autoimmune disease..
President And Fellows Of Harvard College
03/12/15
20150073047

Benzo lipoxin analogues


Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation..
University Of Southern California
03/12/15
20150072986

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.
03/12/15
20150072980

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc
03/12/15
20150072978

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.
03/05/15
20150065507

Novel compounds


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited
03/05/15
20150065352

Monitoring health and disease status using clonotype profiles


There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Sequenta, Inc.
02/26/15
20150057297

Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions


The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, t-cell neoplasms, and cosmetic conditions..
The General Hospital Corporation D/b/a Massachusetts General Hospital
02/26/15
20150056198

Aberrant cell-restricted immunoglobulins provided with a toxic moiety


Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.
02/26/15
20150056185

Immunoglobulin constant region fc receptor binding agents


Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
University Of Maryland, Baltimore
02/19/15
20150051242

Rafamycin analogs and methods for making same


A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mtor inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal.
Zhejiang Zylox Medical Device Co., Ltd.
02/19/15
20150051196

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
02/19/15
20150051178

Estriol therapy for autoimmune and neurodegenerative diseases and disorders


The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period..
The Regents Of The University Of California
02/19/15
20150051089

Quantification of adaptive immune cell genomes in a complex mixture of cells


Compositions and methods are described for highly sensitive quantification of the relative representation of dna from adaptive immune cells (e.g., t and/or b lymphocytes) in dna extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (til), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ..
Adaptive Biotechnologies Corporation
02/19/15
20150050288

Treatment of th17-mediated autoimmune disease via inhibition of stat3


Methods for treating autoimmune disease using one or more inhibitor of stat3 are provided herein. Also disclosed are methods for diagnosing and monitoring autoimmune disease or the propensity to develop autoimmune disease in a subject.
The Johns Hopkins University
02/19/15
20150050210

Pharmaceutical formulation comprising bendamustine


The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives.
Salmon Pharma Gmbh
02/12/15
20150045361

Heterocyclic compounds and their uses


Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.
02/12/15
20150045324

Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity


The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.. .
Hanmi Science Co., Ltd


Popular terms: [SEARCH]

Autoimmune Disease topics: Autoimmune Disease, Immune Disease, Autoimmune, Autoimmune Diseases, Immune Diseases, Transplant, Infectious Disease, Infectious, Inflammatory Disease, Antagonist, Rheumatoid Arthritis, Proliferative, Nucleotide, Antibodies, Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.5022

3917

2 - 1 - 72